Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Cannabinoid Receptors
Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled.
Cannabinoid Receptor Target Files
Related Categories
CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.
| Receptor Subtype | CB1 | CB2 | GPR55 |
|---|
| Transduction Mechanism | ↓Adenylyl Cyclase (Gi/o), ↓ N- and P/Q-type Ca2+ currents, ↑ Kir and A-types K+ currents | ↓ Adenylyl Cyclase (Gi/o) | Activation of Rho family GTPases |
| Primary Distribution | CNS: hippocampus, basal ganglia, cerebellum, cortex, globus pallidus, substantia nigra, pars reticulata | Spleen, tonsils, immune cells | CNS: caudate and putamen |
| Tissue Function | Modulation of neurotransmitter release | Suppression of immune cell function | Pain signaling, control of vascular tone, inflammation |
| Key Compounds | Ki Values (nM) at CB1 | Ki Values (nM) at CB2 |
|---|
| Endogenous Agonists |
Anandamide (1339) 2-Arachidonylglycerol (1298) NADA (1568) Noladin ether (1411) |
61-543 58.3-472 2501 21.2 |
279-1940 145-1400 12001 > 3000 |
| Key CB1 Agonists |
ACEA (1319) ACPA (1318) (R)-(+)-Methanandamide (1121) |
1.4 2.2 17.9-28.3 |
> 2000 715 815-868 |
| Key CB2 Agonists |
CB 65 (2663) GP 1a (2764) GP 2a (2678) GW 405833 (2374)* JWH 015 (1341) JWH 133 (1343) L-759,656 (2434) L-759,633 (2433) |
> 1000 363 900 4772 383 677 4888 1043 |
3.3 0.037 7.6 3.92 13.8 3.4 11.8 6.4 |
| Non-selective Agonists |
CP 55,940 (0949) HU 210 (0966) O-2545 (2680) WIN 55,212-2 (1038) Bay 59-3074 (2500) Δ9-Tetrahydrocannabinol (2741) |
0.5-5.0 0.06-0.73 1.5 5.05 1.89-123 48.3 5.05 |
0.69-2.8 0.17-0.52 0.32 3.13 0.28-16.2 45.5 3.13 |
|
Key CB1 Antagonists/ Inverse Agonists |
AM 251 (1117) AM 281 (1115) LY 320135 (2387) |
7.49 12 141 |
2290 4200 14900 |
|
Key CB2 Antagonists/ Inverse Agonists |
AM 630 (1120) | 5152 | 31.2 |
*partial agonist
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.